The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection

Clinical Microbiology and Infection

Volumn 20, Issue 11, 2014, Pages 1119-1125

  Singh, R ^a   Nieuwdorp, M ^a   ten Berge, I J M ^a   Bemelman, F J ^a   Geerlings, S E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Faecal microbiota transplantation; Inflammatory bowel disease; Irritable bowel syndrome; Multiresistant microorganisms; Obesity; Type 2 diabetes

Indexed keywords

BUTYRIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8;

ABDOMINAL CRAMP; ABDOMINAL TENDERNESS; ANTIBIOTIC RESISTANCE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BIOLOGICAL THERAPY; CONSTIPATION; CROHN DISEASE; DIARRHEA; FAECALIBACTERIUM PRAUSNITZII; FECAL MICROBIOTA TRANSPLANTATION; FEVER; HUMAN; INFLAMMATORY BOWEL DISEASE; INSULIN RESISTANCE; INTESTINE FLORA; IRRITABLE COLON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; ULCERATIVE COLITIS; FECES; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; METABOLIC SYNDROME X; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALIA; CLOSTRIDIUM DIFFICILE;

BIOLOGICAL THERAPY; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84916933903     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12799     Document Type: Review

References (74)

1. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-508.
2. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35: 865-875.
3. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
4. Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin North Am 2012; 41: 781-803.
5. Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 2010; 8: 435-454.
6. Evaldson G, Heimdahl A, Kager L, Nord CE. The normal human anaerobic microflora. Scand J Infect Dis Suppl 1982; 35: 9-15.
7. Stephen AM, Cummings JH. The microbial contribution to human faecal mass. J Med Microbiol 1980; 13: 45-56.
8. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904.
9. Kim MS, Hwang SS, Park EJ, Bae JW. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013; 5: 765-775.
10. Jeffery IB, O'Toole PW. Diet-microbiota interactions and their implications for healthy living. Nutrients 2013; 5: 234-252.
11. Simoes CD, Maukonen J, Scott KP, Virtanen KA, Pietilainen KH, Saarela M. Impact of a very low-energy diet on the fecal microbiota of obese individuals. Eur J Nutr 2014; 53: 1421-1429.
12. Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiol 2012; 7: 91-109.
13. Sha S, Xu B, Wang X et al. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis 2013; 75: 245-251.
14. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 2012; 107: 1452-1459.
15. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007; 13: 2826-2832.
16. Segain JP, Raingeard de la Bletiere D, Bourreille A et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403.
17. Wang W, Chen L, Zhou R et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol 2014; 52: 398-406.
18. Joossens M, Huys G, Cnockaert M et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60: 631-637.
19. Varela E, Manichanh C, Gallart M et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 151-161.
20. Machiels K, Joossens M, Sabino J et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63: 1275-1283.
21. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
22. Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-211.
23. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut 1994; 35(suppl 1): S35-S38.
24. Donohoe DR, Garge N, Zhang X et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011; 13: 517-526.
25. Di Sabatino A, Morera R, Ciccocioppo R et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 2005; 22: 789-794.
26. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503-516.
27. Sha S, Liang J, Chen M et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014; 39: 1003-1032.
28. NCT01240915. A study to investigate the safety and possible clinical benefit of multistem(r) in patients with moderate to severe ulcerative colitis. www.clinicaltrials.gov 2010.
29. NCT01545908. Fecal biotherapy for the induction of remission in active ulcerative colitis. www.clinicaltrials.gov 2012.
30. NCT01650038. Transplantation of faeces in ulcerative colitis; restoring nature's homeostasis (TURN). www.clinicaltrials.gov 2012.
31. NCT01790061. Standardized fecal microbiota transplantation for ulcerative colitis. www.clinicaltrials.gov 2013.
32. NCT01793831. Standardized fecal microbiota transplantation for Crohn's diseases. www.clinicaltrials.gov 2013.
33. NCT01896635. Faecal microbiota transplantation in ulcerative colitis (FOCUS). www.clinicaltrials.gov 2013.
34. NCT01961492. Fecal microbiota transplantation in children with ulcerative colitis. www.clinicaltrials.gov 2013.
35. NCT02033408. Manipulating the microbiome in IBD by antibiotics and FMT. www.clinicaltrials.gov 2013.
36. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55: 392-397.
37. Chassard C, Dapoigny M, Scott KP et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-838.
38. Matsunami M, Tarui T, Mitani K et al. Luminal hydrogen sulfide plays a pronociceptive role in mouse colon. Gut 2009; 58: 751-761.
39. Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 2011; 60(Pt 6): 817-827.
40. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512-519.
41. Kerckhoffs AP, Samsom M, van der Rest ME et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887-2892.
42. Ford AC, Quigley EM, Lacy BE et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547-1561.
43. Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, Nieuwdorp M. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol 2013; 27: 127-137.
44. NCT02092402. Fecal microbiota transplantation in patients with irritable bowel syndrome. www.clinicaltrials.gov 2014.
45. Shukla A, Kumar K, Singh A. Association between obesity and selected morbidities: a study of BRICS countries. PLoS One 2014; 9: e94433.
46. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104: 979-984.
47. Rabot S, Membrez M, Bruneau A et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J 2010; 24: 4948-4959.
48. Kootte RS, Vrieze A, Holleman F et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-120.
49. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723.
50. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3: 213-223.
51. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137: 1716-1724.
52. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
53. Kocelak P, Zak-Golab A, Zahorska-Markiewicz B et al. Resting energy expenditure and gut microbiota in obese and normal weight subjects. Eur Rev Med Pharmacol Sci 2013; 17: 2816-2821.
54. Schwiertz A, Taras D, Schafer K et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010; 18: 190-195.
55. Million M, Angelakis E, Maraninchi M et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes 2013; 37: 1460-1466.
56. Million M, Raoult D. The role of the manipulation of the gut microbiota in obesity. Curr Infect Dis Rep 2013; 15: 25-30.
57. Wolever TM, Spadafora P, Eshuis H. Interaction between colonic acetate and propionate in humans. Am J Clin Nutr 1991; 53: 681-687.
58. Vernay M. Origin and utilization of volatile fatty acids and lactate in the rabbit: influence of the faecal excretion pattern. Br J Nutr 1987; 57: 371-381.
59. Masoro EJ, Porter E. Propionic acid as a precursor in the biosynthesis of animal fatty acids. J Lipid Res 1961; 2: 177-181.
60. Larsen N, Vogensen FK, van den Berg FW et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085.
61. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.
62. Gao Z, Yin J, Zhang J et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509-1517.
63. NCT02050607. Fecal microbiota transplantation for the treatment of metabolic syndrome. www.clinicaltrials.gov 2013.
64. Vrieze A, Out C, Fuentes S et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014; 60: 824-831.
65. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579-587.
66. Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis 2012; 25: 385-394.
67. Graffunder EM, Preston KE, Evans AM, Venezia RA. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005; 56: 139-145.
68. Reddy P, Malczynski M, Obias A et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007; 45: 846-852.
69. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230.
70. Willing BP, Vacharaksa A, Croxen M, Thanachayanont T, Finlay BB. Altering host resistance to infections through microbial transplantation. PLoS One 2011; 6: e26988.
71. Vallance BA, Deng W, Jacobson K, Finlay BB. Host susceptibility to the attaching and effacing bacterial pathogen Citrobacter rodentium. Infect Immun 2003; 71: 3443-3453.
72. Ubeda C, Bucci V, Caballero S et al. Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun 2013; 81: 965-973.
73. Singh R, van Nood E, Nieuwdorp M et al. Donor faeces infusion for eradication of extended-spectrum β-lactamase-producing Escherichia coli in a patient with end-stage renal disease. Clin Microbiol Infect 2014; [Epub ahead of print].
74. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790-801.